|Mr. Michael Amoroso||Pres, CEO & Director||876.24k||N/A||1978|
|Dr. Derek Jantz Ph.D.||Co-Founder, Chief Scientific Officer & Strategy||597.38k||N/A||1976|
|Mr. John Alexander Kelly||Chief Financial Officer||691.14k||N/A||1967|
|Dr. Jefferson J. Smith Ph.D.||Co-Founder & Chief Research Officer||N/A||N/A||N/A|
|Mr. Shane Barton||VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1971|
|Mei Burris||Director of Investor Relations & Fin.||N/A||N/A||N/A|
|Mr. Dario Scimeca||Gen. Counsel & Sec.||N/A||N/A||1975|
|Mr. Bruce Stevens||VP of Quality & Compliance||N/A||N/A||N/A|
|Ms. Heather King||Director of Marketing Communications & PR||N/A||N/A||N/A|
|Maurissa Messier||Sr. Director of Corp. Communications||N/A||N/A||N/A|
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences, Inc.’s ISS governance QualityScore as of 1 December 2022 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 8; Compensation: 7.